You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH)與喜鵲醫藥簽訂框架協議 謀求現代中藥和植物藥創新領域發展
格隆匯 02-26 18:00

格隆匯2月26日丨康恩貝(600572.SH)公佈,公司擬出資5000萬元人民幣以增資方式取得廣州喜鵲醫藥有限公司(以下簡稱“喜鵲醫藥”)5.6995%的股權。截止目前,上述投資事項尚未簽署正式投資協議,相關工作正在推進當中。

為發揮各自的優勢資源,從股權、技術、項目、人才等層面建立面向未來的戰略合作關係,共同謀求在現代中藥和植物藥的創新領域可持續發展,近日,公司與喜鵲醫藥簽訂了《浙江康恩貝製藥股份有限公司與廣州喜鵲醫藥有限公司之戰略合作框架協議書》。

《合作框架協議》的簽訂有利於公司依託喜鵲醫藥獨具特色的藥物設計理念和研發優勢,積極響應國家關於“促進中醫藥傳承創新發展”發展戰略,通過資源整合、取長補短,謀求在現代中藥和植物藥的創新領域可持續發展,符合公司的戰略需要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account